CA2146007C - Substituted quinuclidines - Google Patents

Substituted quinuclidines

Info

Publication number
CA2146007C
CA2146007C CA002146007A CA2146007A CA2146007C CA 2146007 C CA2146007 C CA 2146007C CA 002146007 A CA002146007 A CA 002146007A CA 2146007 A CA2146007 A CA 2146007A CA 2146007 C CA2146007 C CA 2146007C
Authority
CA
Canada
Prior art keywords
carbon atoms
alkyl
compound
substituted
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002146007A
Other languages
English (en)
French (fr)
Other versions
CA2146007A1 (en
Inventor
Fumitaka Ito
Toshihide Kokura
Masami Nakane
Kunio Satake
Hiroaki Wakabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CA2146007A1 publication Critical patent/CA2146007A1/en
Application granted granted Critical
Publication of CA2146007C publication Critical patent/CA2146007C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CA002146007A 1992-10-28 1993-09-30 Substituted quinuclidines Expired - Fee Related CA2146007C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP290569/92 1992-10-28
JP4290569A JP2656700B2 (ja) 1992-10-28 1992-10-28 置換キヌクリジン誘導体

Publications (2)

Publication Number Publication Date
CA2146007A1 CA2146007A1 (en) 1994-05-11
CA2146007C true CA2146007C (en) 1999-02-23

Family

ID=17757724

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002146007A Expired - Fee Related CA2146007C (en) 1992-10-28 1993-09-30 Substituted quinuclidines

Country Status (14)

Country Link
EP (1) EP0665843B1 (fi)
JP (1) JP2656700B2 (fi)
AT (1) ATE247113T1 (fi)
AU (1) AU5141293A (fi)
CA (1) CA2146007C (fi)
DE (1) DE69333143T2 (fi)
DK (1) DK0665843T3 (fi)
ES (1) ES2202313T3 (fi)
FI (1) FI114637B (fi)
HU (1) HUT65831A (fi)
IL (1) IL107346A0 (fi)
MX (1) MX9306704A (fi)
PT (1) PT665843E (fi)
WO (1) WO1994010170A1 (fi)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
DK0708771T3 (da) * 1993-07-15 1999-06-21 Pfizer Benzyloxyquinuclidiner som substans P antagonister
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
DK0719253T3 (da) * 1993-09-17 2004-07-26 Pfizer 3-amino-5-carboxy-substituerede piperidiner og 3-amino-4-carboxy-substituerede pyrrolidiner som tachykininantagonister
EP0790825A1 (en) * 1994-11-10 1997-08-27 Pfizer Inc. Nk-1 receptor antagonists for the treatment of eye disorders
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
KR102072631B1 (ko) 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140046059A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Process for the preparation of morpholino sulfonyl indole derivatives
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
DE9290057U1 (de) * 1991-05-22 1994-01-05 Pfizer Substituierte 3-Aminochinuclidine
JP2719063B2 (ja) * 1991-05-22 1998-02-25 ファイザー製薬株式会社 置換３−アミノキヌクリジンｐ物質拮抗剤

Also Published As

Publication number Publication date
ES2202313T3 (es) 2004-04-01
DE69333143D1 (de) 2003-09-18
HUT65831A (en) 1994-07-28
FI934752A0 (fi) 1993-10-27
AU5141293A (en) 1994-05-24
JP2656700B2 (ja) 1997-09-24
FI114637B (fi) 2004-11-30
HU9303051D0 (en) 1994-01-28
ATE247113T1 (de) 2003-08-15
DE69333143T2 (de) 2004-02-26
EP0665843A1 (en) 1995-08-09
JPH06135964A (ja) 1994-05-17
FI934752A (fi) 1994-04-29
IL107346A0 (en) 1994-01-25
PT665843E (pt) 2003-12-31
DK0665843T3 (da) 2003-12-01
CA2146007A1 (en) 1994-05-11
EP0665843B1 (en) 2003-08-13
WO1994010170A1 (en) 1994-05-11
MX9306704A (es) 1995-01-31

Similar Documents

Publication Publication Date Title
CA2146007C (en) Substituted quinuclidines
EP0665844B1 (en) Substituted benzylaminoquinuclidines as substance p antagonists
EP0632809B1 (en) Quinuclidine derivatives as substance p antagonists
AP120A (en) Quinuclidine therapeutic agents
EP0573522B1 (en) 1-azabicyclo[3.2.2]nonan-3-amine derivatives
US5422354A (en) Quinuclidine derivatives
EP0532527B1 (en) 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
PL170513B1 (en) Method of obtaining novel derivatives of 3-amino quinuclidine
AU2481292A (en) Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
CZ301209B6 (cs) Nové chinuklidinové deriváty a medicinální kompozice s jejich obsahem
US5604241A (en) Substituted benzylaminoquinuclidines as substance P antagonists
US5569662A (en) Quinuclidine derivatives as substance P antagonists
US5837711A (en) Substituted quinuclidines as substance P antagonists
MXPA00002030A (en) 2-aminopyridines containing fused ring substituents as nos inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed